Please provide your email address to receive an email when new articles are posted on . Continued lecanemab treatment linked to significant disease-modifying effects. No new safety signals were ...

Please provide your email address to receive an email when new articles are posted on . The newly presented data is from the two STOP-HS trials, both of which met their primary endpoints. Povorcitinib ...

As organizations seek to evolve their patient support programs, five key actions can help bridge the data gap between analytics teams and patient care teams: Data will always be essential in measuring ...

Results of two Chinese phase 3 trials presented at this year’s San Antonio Breast Cancer Symposium (SABCS) 2025 provide strong support for adjuvant carboplatin in early-stage triple-negative breast ...

Venetoclax-obinutuzumab therapy shows sustained PFS and OS benefits over chemoimmunotherapy in untreated CLL patients with coexisting conditions. The CLL14 trial's 6-year follow-up confirms >50% of ...